Sana Biotechnology

### Executive Summary Sana Biotechnology raised $405.8M in a Regulation D private placement, signaling strong institutional confidence in synthetic biology and intracellular mRNA delivery. The first sale date of 2025-10-12 indicates this capital was deployed months before the filing, suggesting rapid execution. Key backers include Andreessen Horowitz and Sands Capital, both listed as related persons. ### Investor Edge Watch for a potential D/A amendment (Form D/A) that could indicate additional capital or changed terms, signaling either strong demand or restructuring. Also monitor for any public filing (S-1) or reverse merger that would bring this private company public. ### Sector capital positioning This $405.8M raise is one of the largest private synthetic biology rounds in recent years, reinforcing a capital flow trend toward mRNA delivery platforms and programmable biology. ### Convergence Signals No direct public signals are evident from the filing data, but the involvement of Andreessen Horowitz (a16z) suggests potential ties to broader biotech or AI-driven drug discovery trends. No patents, contracts, or legislation are mentioned. ### Key Takeaways - Sana Biotechnology raised $405.8M in a private placement, one of the largest in synthetic biology. - First sale occurred 2025-10-12, indicating capital was raised months before the filing. - Andreessen Horowitz and Sands Capital are listed as related persons, signaling top-tier investor involvement. ### Risk Indicators & Flags No D/A amendments noted; this is an initial Form D. The large amount ($405.8M) for a private company in synthetic biology may attract regulatory scrutiny. No public ticker or exit path is disclosed, increasing liquidity risk for investors. ### Verification & References Filing is a Form D (initial notice) with SEC accession 0001702600-24-20167. Verify at https://www.sec.gov/cgi-bin/browse-edgar?company=Sana%20Biotechnology&type=D&action=getcompany. First sale date 2025-10-12 is verifiable in the filing. Related persons Andreessen Horowitz and Sands Capital are listed as officers/directors, not necessarily capital sources.